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A single steroid 
injection into 
the knee joint 
causes acute 
hyperglycemia 
for 2 or 3 days 
in patients with 
diabetes who 
otherwise have 
good glucose 
control.
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CONTINUED
Evidence summary 
Two prospective cohort studies evaluated the 
eff ect on glycemic control of a single gluco-
corticoid injection into the knee of patients 
with controlled type 2 diabetes (glycosylated 
hemoglobin A1c 7.0%). Th e fi rst enrolled 
9 patients with symptomatic osteoarthritis of 
the knee unresponsive to 3 months of nonste-
roidal anti-infl ammatory drugs (NSAIDs).1 
All received a 50-mg injection of methylpred-
nisolone acetate after maximal aspiration of 
any joint fl uid. No changes were made to the 
diabetes care regimen, including medication, 
diet, or exercise prescriptions. 
With self-monitoring 6 times a day dur-
ing the week after the injection, 7 patients 
showed an increase over baseline blood glu-
cose levels of more than 2 standard devia-
tions; values typically rose above 300 mg/dL. 
Peak blood sugar elevation occurred 5 to 84 
hours after injection; the hyperglycemic ef-
fect lasted for 2 or 3 days. 
In a second cohort study, 6 patients re-
ceived a knee injection of 1 mL Celestone 
Chronodose (3 mg betamethasone acetate 
and 3 mg betamethasone sodium phos-
phate, comparable in anti-infl ammatory 
and glucocorticoid potency to 32 mg methyl-
prednisolone acetate).2 Patients moni-
tored their blood glucose 6 times a day for 
1 week; investigators measured fructosamine 
levels (a measure of intermediate-term
glucose control) at baseline and again 
2 weeks after injection. 
Th e injection produced hyperglycemia in 
all participants, with peak blood glucose lev-
els ranging from 251 to 430 mg/dL and time to 
peak glucose usually less than 6 hours.  Fruc-
tosamine levels didn’t change signifi cantly. 
No change in glucose 
after a single shoulder injection
Two studies evaluated the eff ect of a single 
shoulder injection. One prospective cohort 
study included 18 patients with diabetes 
(type not specifi ed, mean A1c=7.6%).3 All 
had shoulder pain unresponsive to NSAIDs 
for more than a month, had not changed 
diabetes medications within the preceding 
2 weeks, and had not had steroid therapy 
within the preceding 3 months. 
All patients received a single injection 
containing 35 mg methylprednisolone ac-
etate into the anterior glenohumeral joint. 
Th ey monitored their blood glucose levels 
6 times a day for 1 week and had a fructos-
amine level drawn before injection and 
2 weeks afterward. Th e injection produced no 
signifi cant change in mean blood glucose or 
fructosamine levels. 
 Do intra-articular steroid 
injections aff ect glycemic control 
in patients with diabetes? 
EVIDENCE-BASED ANSWER
A  yes, but the clinical importance   is minimal. A single intra-articular 
steroid injection into the knee produces 
acute hyperglycemia for 2 or 3 days in pa-
tients with diabetes who otherwise have 
good glucose control (strength of recom-
mendation [SOR]: B, small cohort studies). 
Intra-articular steroid injections into the 
shoulder may briefl y raise postprandial (but 
not mean) glucose levels with larger and re-
peated doses (SOR: C, extrapolated from het-
erogenous and mixed cohort studies).
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But repeated shoulder injections
raise postprandial glucose
In contrast, another prospective cohort study 
followed 11 patients (8 with diabetes) who re-
ceived 3 injections of 3.75 mg cortivazol (com-
parable to 50 mg methylprednisolone acetate) 
at 3-day intervals into 1 shoulder joint.4 In-
vestigators checked fasting and postprandial 
glucose levels before the fi rst injection and on 
post-treatment days 1, 7, and 21. 
Th e shoulder injections elevated post-
prandial glucose levels (from 17060 
mg/dL at baseline to 258100 mg/dL on 
day 1 and 25287 mg/dL on day 7; P.05 
for both comparisons). Mean fasting glucose 
levels didn’t change, however.
Recommendations
Th e American Academy of Orthopedic Sur-
geons treatment guidelines for osteoarthritis 
of the knee don’t discuss possible adverse ef-
fects from steroid injections.5 Th e American 
Diabetes Association makes no recommen-
dations regarding steroid injections in pa-
tients with diabetes.                               JFP
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If the golden rule of medi-cine is “First, do no harm,” some experts in infectious diseases think the major-
ity of clinicians are dropping the 
ball—at least when it comes to 
infl uenza vaccination. For years, 
the rate of vaccination against 
fl u among health care person-
nel has been “unacceptably low,” 
in the words of Neil Fishman, 
MD, President of the Society 
for Healthcare Epidemiology of 
America (SHEA), “despite Her-
culean efforts to increase it.”
Now, SHEA and other pro-
fessional medical organizations 
think it may be time to take the 
gloves off (fi guratively, of course). 
The organization recently pub-
lished a position paper in Infec-
tion Control and Hospital Epide-
miology in which it “endorses a 
policy in which annual infl uenza 
vaccination is a condition of both 
initial and continued [health care 
personnel] employment and/
or professional privileges.” The 
recommendation applies to all 
health care providers (and other 
workers) in all settings, as well as 
students and volunteers.
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As health technology and methodology advance, the need for continued learn-
ing and scholarly activities has 
driven many of us to pursue 
advanced degrees. Many are 
poised in various states of com-
pletion, with as many reasons 
for being stalled in one stage 
as there are degree programs. 
Recently, in a conversation with 
friends, we reminisced about 
our “all-but-dissertation” days. 
While the pain of the process 
has fi nally become a mere wince 
in recollection, the memory of 
how much support we each re-
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